PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
9702850-0	1998	Effects of ABT-761, a novel 5-lipoxygenase inhibitor, on the pharmacokinetics of a single dose of ethinyl estradiol and levonorgestrel in healthy female volunteers.	atreleuton	11-18	arachidonate 5-lipoxygenase	Homo sapiens	28-42
11527015-1	2001	Abbott"s ABT-761 is a 5-lipoxygenase inhibitor with 8-fold increased potency over Bay-X-1005 and 150-fold over zileuton [171665].	atreleuton	9-16	arachidonate 5-lipoxygenase	Homo sapiens	22-36
9923573-0	1998	Pharmacokinetics of a novel 5-lipoxygenase inhibitor (ABT-761) in pediatric patients with asthma.	atreleuton	54-61	arachidonate 5-lipoxygenase	Homo sapiens	28-42
9702850-1	1998	ABT-761 is a second-generation 5-lipoxygenase inhibitor in clinical development for the treatment of asthma.	atreleuton	0-7	arachidonate 5-lipoxygenase	Homo sapiens	31-45
9596112-1	1998	The novel 5-lipoxygenase (5-LO) inhibitor, ABT-761, was investigated for its effect on exercise-induced bronchoconstriction in asthmatic subjects.	atreleuton	43-50	arachidonate 5-lipoxygenase	Homo sapiens	10-24
10099073-1	1998	ABT-761 is a second-generation 5-lipoxygenase inhibitor for the treatment of asthma.	atreleuton	0-7	arachidonate 5-lipoxygenase	Homo sapiens	31-45
9596112-10	1998	We conclude that ABT-761 is effective in suppressing exercise-induced bronchoconstriction and that this protection is related quantitatively to the degree of 5-lipoxygenase inhibition.	atreleuton	17-24	arachidonate 5-lipoxygenase	Homo sapiens	158-172
9365125-8	1997	The specific lipoxygenase inhibitors zileuton and ABT-761 given 30 min before eotaxin caused a 63-79% reduction in the level of eosinophils seen in the lavage fluid.	atreleuton	50-57	chemokine (C-C motif) ligand 11	Mus musculus	78-85
9569998-0	1998	Dose-proportional pharmacokinetics of a new 5-lipoxygenase inhibitor, ABT-761, in healthy volunteers.	atreleuton	70-77	arachidonate 5-lipoxygenase	Homo sapiens	44-58
9569998-1	1998	ABT-761, a new potent 5-lipoxygenase inhibitor, is under development for the treatment of asthma.	atreleuton	0-7	arachidonate 5-lipoxygenase	Homo sapiens	22-36
9311617-9	1997	The culmination of this effort contributed to the discovery of ABT-761, a 5-lipoxygenase inhibitor with in vivo duration in monkey improved 40-fold over thefirst generation inhibitor.	atreleuton	63-70	arachidonate 5-lipoxygenase	Homo sapiens	74-88
9117020-0	1997	The effect of ABT-761, a novel 5-lipoxygenase inhibitor, on exercise- and adenosine-induced bronchoconstriction in asthmatic subjects.	atreleuton	14-21	arachidonate 5-lipoxygenase	Homo sapiens	31-45
27883201-0	2017	Effect of treatment with 5-lipoxygenase inhibitor VIA-2291 (atreleuton) on coronary plaque progression: a serial CT angiography study.	atreleuton	50-58	arachidonate 5-lipoxygenase	Homo sapiens	25-39
27883201-0	2017	Effect of treatment with 5-lipoxygenase inhibitor VIA-2291 (atreleuton) on coronary plaque progression: a serial CT angiography study.	atreleuton	60-70	arachidonate 5-lipoxygenase	Homo sapiens	25-39
20190281-0	2010	Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome.	atreleuton	40-48	arachidonate 5-lipoxygenase	Homo sapiens	15-29
20190281-0	2010	Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome.	atreleuton	50-60	arachidonate 5-lipoxygenase	Homo sapiens	15-29
31983575-0	2020	Effect of 5-lipoxygenase inhibitor, VIA-2291 (Atreleuton), on epicardial fat volume in patients with recent acute coronary syndrome.	atreleuton	46-56	arachidonate 5-lipoxygenase	Homo sapiens	10-24
25752438-0	2015	A phase 2 randomized, double-blind, placebo-controlled study of the effect of VIA-2291, a 5-lipoxygenase inhibitor, on vascular inflammation in patients after an acute coronary syndrome.	atreleuton	78-86	arachidonate 5-lipoxygenase	Homo sapiens	90-104